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CRANIum, a cross-sectional epidemiology study in Western Europe and Canada, was conducted to describe and
compare the prevalence of a positive screen for neurocognitive impairment (NCI), depressive symptoms, and anxiety in
an HIV-positive population either receiving combination antiretroviral therapy (cART) or who were naive to
antiretroviral therapy (ART). HIV-positive patients ≥18 years of age attending a routine medical follow-up visit and
able to complete the designated screening tools were eligible for study inclusion. The Brief Neurocognitive Screen was
used to assess NCI; depressive and anxiety symptoms were assessed using the Hospital Anxiety and Depression Scale.
The evaluable patient population (N = 2863) included 1766 men (61.7%) and 1096 (38.3%) women. A total of 1969
patients were cART-experienced (68.8%), and 894 were ART-naive (31.2%). A positive screen for NCI was found in
41.5% of patients (cART-experienced, 42.5%; ART-naive, 39.4%; p = 0.12). A positive screen for depressive symptoms
was found in 15.7% of patients (cART-experienced, 16.8%; ART-naive, 13.3%; p = 0.01), whereas 33.3% of patients
screened positive for anxiety (cART-experienced, 33.5%; ART-naive, 32.8%; p = 0.71). A greater percentage of women
compared with men screened positive for NCI (51.78% vs. 35.1%; p < 0.0001) and depressive symptoms (17.9% vs.
14.3%; p = 0.01). These data suggest that neurocognitive and mood disorders remain highly prevalent in HIV-infected
patients. Regular mental health screening in this population is warranted.
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Introduction
Infection with HIV is often preceded or accompanied by
neuropsychiatric conditions including mood and person-
ality disorders and psychosis (Bennett, Joesch, Mazur, &
Roy-Byrne, 2009; Gaynes, Pence, Eron, & Miller, 2008;
Owe-Larsson, Sall, Salamon, & Allgulander, 2009).
Depression is the most prevalent psychiatric disorder
among patients infected with HIV with a prevalence up
to four times that of the general population (Bing et al.,
2001). Suicides and anxiety disorders are more common
among patients with HIV than uninfected individuals
(Hinkin, Castellon, Atkinson, & Goodkin, 2001; Keiser
et al., 2010; Sewell et al., 2000). In addition, neurocog-
nitive impairment (NCI) is often associated with HIV
infection (Chan, Kandiah, & Chua, 2012; Heaton et al.,
2010; Lawler et al., 2011; Robertson et al., 2007). These
disorders may affect quality of life and can contribute
to increased morbidity and mortality (Andrinopoulos
et al., 2011; Bing et al., 2000; Charles et al., 2012;
Grov, Golub, Parsons, Brennan, & Karpiak, 2010;
Hessol et al., 2007; Ickovics et al., 2001; Li, Lee,
Thammawijaya, Jiraphongsa, & Rotheram-Borus, 2009;
Reis et al., 2011; Tozzi et al., 2004; Wilkie et al., 1998;
Wisniewski et al., 2005). A recently described meta-
analysis found that the treatment of depression among
HIV-infected individuals led to increases in antiretroviral
adherence (Sin & DiMatteo, 2014).
This study was conducted to describe and compare
the prevalence of a positive screening for NCI, anxiety,
and/or depressive symptoms in an HIV-positive popula-
tion receiving combination antiretroviral therapy (cART)
versus antiretroviral therapy-naive (ART-naive) patients,
and to explore potential associations between prevalence
and sociodemographic and HIV disease characteristics.
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Methods
Study design
CRANIum (sCReen for Anxiety, depression, and Neu-
rocognitive Impairment in HIV+ patients) was a multi-
national, multicenter, cross-sectional epidemiology
study, conducted among patients with HIV in Western
Europe and Canada from October 2010 to June 2011.
The study aimed to include ART-naive patients and
patients treated with ritonavir-boosted protease inhibitors
and nonnucleoside reverse transcriptase inhibitors in a
1:1:1 ratio. An a-priori recruitment target of 40% female
subjects was set for the overall study population. The
primary objective of the study was to describe and
compare the prevalence of a positive screen for NCI,
depression, and anxiety in an HIV-infected population
either receiving or naive to cART.
Study population
Patients were eligible for enrollment if they were
infected with HIV, ≥18 years of age, attending a routine
medical follow-up visit, and able to complete the
designated screening tools. Patients receiving cART
were required to be on their current antiretroviral
regimen for ≥9 months. Exclusion criteria included a
current or active opportunistic infection or malignancy of
the central nervous system (CNS) and alcohol (>5 units/
day) or illicit substance abuse within the previous three
months. The study protocol was approved by the
appropriate institutional review boards or independent
ethics committees. Approved informed consent was
obtained from subjects before enrollment.
Variables and instruments
NCI was assessed by the Brief Neurocognitive Screen
(BNCS), a validated, but limited, screening (not dia-
gnostic) tool (Ellis et al., 2005; Reitan & Wolfson, 1985;
Wechsler, 1981). A positive screen for NCI per indi-
vidual patient was defined as a z-score of one standard
deviation below the mean on two tests or two standard
deviations below the mean on one test (Heaton, Miller,
Taylor, & Grant, 2004). Depressive and anxiety symp-
tomatology were assessed using the self-administered
Hospital Anxiety and Depression Scale (HADS) ques-
tionnaire, which consists of seven items each relating to
depression (HADS-D) and anxiety (HADS-A), respect-
ively. A score of ≥8 on the HADS-D and HADS-A
subscales (Zigmond & Snaith, 1983) was considered a
positive screen.
Statistical analysis
A total of 2575 patients was determined to provide 80%
power to detect a difference in prevalence of 20–25%
between treatment groups at a 5% significance level. (See




A total of 2884 patients from 15 countries in Western
Europe and Canada were enrolled. The evaluable patient
population (n = 2863) included 1766 men (61.7%) and
1096 women (38.3%; see online Supplementary Figure 1
for patient disposition). Demographic characteristics of
patients are described in Table 1. The mean age of patients
was 42.9 years (range, 19–83). Most patients were male
(n = 1766 [61.7%] and white (n = 2256 [78.8%]), with a
median HIV-1 RNA level of 633.5 copies/mL and a mean
CD4+ T-cell nadir of 295 cells/µL.
Neurocognitive impairment
Among the evaluable patients, 41.5% screened positive
for NCI. Of the ART-naive patients, 39.4% (352/894)
screened positive for NCI, whereas 42.5% of cART-
experienced patients (836/1969) screened positive for
NCI (p = 0.12; Figure 1). Factors associated with NCI
are shown in Figure 2A.
Depression and anxiety
Among the evaluable patients, 15.7% screened positive
for depression and 33.3% screened positive for anxiety
(Figure 1A). A significantly greater percentage of cART-
experienced patients (326/1941 [16.8%]) screened posit-
ive for depression compared with ART-naive patients
(117/882 [13.3%]; p = 0.01), whereas the percentage of
patients screening positive for anxiety was similar
between ART-naive (290/884 [32.8%]) and cART-
experienced patients (648/1933 [33.5%]; p = 0.71).
Factors associated with a positive screen for depressive
symptoms and for anxiety are shown in Figure 2B and
C, respectively.
Gender analysis
Women comprised nearly 40% of the study population.
The proportion of black patients was significantly higher
among women than men (25.8% vs. 5.9%; p < 0.0001). A
greater proportion of men completed secondary or higher
education (87.3% vs. 73.7%; p < 0.0001). Men were more
likely to smoke or to use alcohol or illegal substances.
Women who were cART-experienced had a significantly
lower CD4+ T-cell count nadir (203.4 cells/µL) than
cART-experienced men (228.2 cells/µL; p = 0.0017).
Additional demographic data based on gender can be
found in the online Supplementary Table 1.
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There was a significantly higher percentage of women
with a positive screen for NCI compared with men (51.7%
vs. 35.1%; p < 0.0001; Figure 1B). This difference was
consistent among the cART-experienced (52.3% women
vs. 34.8% men; p < 0.0001) and ART-naive populations
(49.8% women vs. 35.7% men; p < 0.0001). In patients
with a negative screen for depression (HADS-D < 8, n =
2380), 48.5% of women versus 33.7% of men (p < 0.0001)
had a positive screen for NCI.
A significantly greater percentage of women screened
positive for depression (17.9%) compared with men
(14.3%; p = 0.01), driven by differences observed in the
ART-naive group (20.8% women; 10.6% men; p <
0.0001; Figure 1B). Differences between genders for a
positive screen for anxiety did not reach statistical
significance overall (women 35.3%; men 32.0%; p =
0.07) but were significantly higher in the ART-naive
group (39.1% women; 30.6% men; p = 0.02; Figure 1B).
Discussion
In CRANIum, more than 40% of the patients infected
with HIV screened positive for NCI, similar to the rate
reported in an earlier study (Heaton et al., 2011).
The prevalence of a positive screen for NCI was not
statistically different between patients who were cART-
experienced and ART-naive; however, differences in
demographics and disease characteristics between the
groups should be considered. Patients treated with cART
who had a lower viral load (≤50 copies/mL) were less
likely to screen positive for NCI. Gender subgroup
analysis demonstrated that women were significantly
more likely to screen positive for NCI than men,
independent of receipt of cART. Although significant
differences in demographic and HIV disease character-
istics were found between genders (a greater proportion
of women were black and unemployed, and fewer
women had a secondary or higher education), female
gender was identified as a risk factor in the multivariate
analysis.
Approximately one-third of the patients in this study
screened positive for anxiety, and approximately 16%
screened positive for depressive symptomatology.
The percentage of patients who screened positive for
depressive symptoms in this study is approximately twice
Figure 1. (A) Positive screen of total, ART-naive, and cART-experienced patients infected with HIV for NCI (BNCS), anxiety
(HADS-A), or depression (HADS-D). (B) Neuropsychologic screen of total, ART-naive, and cART-experienced patients infected with
HIV stratified by gender. Positive screen for NCI (left panel), positive screen for depressive symptoms (center panel), positive screen
for anxiety (right panel); total (n = 2863), ART-naive (n = 894), cART-experienced (n = 1969). ART = antiretroviral therapy; cART =
combination antiretroviral therapy; HADS = Hospital Anxiety and Depression Scale; NCI = neurocognitive impairment.
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that previously reported for depression in the general
European population (Ayuso-Mateos et al., 2001).
Compared with men, a higher proportion of women
screened positive for depressive symptoms; however,
significant differences in demographic and disease
characteristics were found between the genders; being
female was not an identified risk factor for a positive
screen for depression in multivariate analysis. The
prevalence of depressive symptoms among women
infected with HIV in this study is nearly twice that
reported for women in the general European population
(Ayuso-Mateos et al., 2001). Previous studies have
concluded that depression and depressive symptomato-
logy seem more prevalent and severe in HIV-infected
women compared with HIV-infected men (Kinyanda,
Hoskins, Nakku, Nawaz, & Patel, 2011; Reis et al., 2011;
Table 1. Demographic data and disease characteristics.
All subjects ART-naive cART-experienced P value*
Evaluable subjects, n (%) 2863 (100) 894 (31.2) 1969 (68.8)
Age (years), mean 42.9 38.0 45.2 <0.0001
Men (%) 61.7 73.7 56.2 <0.0001
Race (%) 0.1367
White 78.8 80.1 78.2
Black 13.5 11.6 14.4
Other 7.7 8.3 7.4
Unemployed (%) 33.2 22.5 38.0 <0.0001
Marital status – single (%) 51.5 58.3 48.5 <0.0001
Any children (%) 39.4 28.1 44.5 <0.0001
Residence (%) 0.0144
Rural 9.3 7.7 10.0
City 67.0 70.6 65.4
Small/large town 22.9 21.4 22.6
Secondary school or higher education (%) 82.1 86.8 80.1 <0.0001
Risk factor for acquiring HIV (%) <0.0001
Homosexual 43.3 57.7 36.8
Heterosexual 45.8 38.5 49.1
Other/not known 10.9 3.8 14.1
Duration of HIV infection (months), mean 98.1 42.5 126.9 <0.0001
Last-recorded HIV-1 RNA (c/mL), median 633.5 22,390 <50 <0.0001
Last-recorded CD4+ T-cell count (cells/µL), mean 587 554 600 <0.0001
CD4+ T-cell count nadir (cells/µL), mean 295 474 217 <0.0001
AIDS diagnosis (%) 17.5 2.5 24.4 <0.0001
Alcohol use (%) <0.0001
None 38.8 30.7 42.5
Intermittent (≤2 times/week) 46.3 52.8 43.4
Regular (3–6 times/week) 9.1 12.0 7.8
Daily 3.6 3.0 3.9
Ex-drinker (none in the last three months) 2.2 1.5 2.5
Illegal substance use in the previous 12 months (%) 11.2 17.5 8.4 <0.0001
Previous CNS infection (%) 4.5 0.6 6.3 <0.0001
Previous psychiatric diagnosis (%) 20.1 15.7 22.2 <0.0001
Other chronic diseases (%)
Hepatitis C coinfection 12.4 5.3 15.6 <0.0001
Hepatitis B coinfection 4.8 2.8 5.7 0.0008
Diabetes 3.0 1.6 3.7 0.0020
Hyperlipidemia 12.3 4.5 15.8 <0.0001
High blood pressure 9.2 6.3 10.5 0.0003
Treated with antidepressives (%) 7.4 5.0 8.5 0.0009
Treated with anxiolytics (%) 5.0 3.7 5.6 0.0310
ART = antiretroviral therapy; cART = combination antiretroviral therapy; CNS = central nervous system.
*ART-naive vs. cART-experienced.
Rates may not add up to 100% because of rounding.
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Turner, Laine, Cosler, & Hauck, 2003). The high number
and percentage of women included in this study (n =
1096, 38.3%) provide robust data.
Due to the cross-sectional nature of this study, the
interpretation of predictive associations between risk
factors and outcomes is difficult and does not demon-
strate causality. Limitations of this study include the use
of screening tools rather than structured or semistruc-
tured diagnostic interviews to diagnose depression and
anxiety. Moreover, only three tests, and not a complete
battery, were used to evaluate NCI. Additionally, this
study used normalized data for the prevalence of
neuropsychologic conditions from a US population;
normative data from each of the countries that enrolled
subjects in the study were not available, and the local
differences in population risk may have an impact on the
impairment assessed. Because the prevalence of NCI in
the general population is most often provided for older
adults, comparison of the population in this study (mean
age 42.9 years) with an age-matched historical control is
difficult.
Strengths of our study comprise both the large
overall and female populations included. The subjects
in this study were residents of a wide geographic area
encompassing 15 countries, whereas most previous
studies have tended to focus on individual countries
(Chan et al., 2012; Gaynes et al., 2008; Kinyanda et al.,
2011; Pappin, Wouters, & Booysen, 2012). Nonetheless,
the rates of impairment observed in this study are
comparable to those seen in other studies (Chan et al.,
2012; Gaynes et al., 2008; Pappin et al., 2012).
Neuropsychological and psychiatric symptoms in the
HIV population have obvious implications for treatment
and serve as a reminder to health-care providers of the
importance of comorbid mental health issues and
neurocognitive functioning. Data in this study suggest
that screenings for NCI, depression, and anxiety should
be included in the routine clinical HIV management
algorithms, especially for patients with identified risk
factors.
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